JP2023534808A5 - - Google Patents

Info

Publication number
JP2023534808A5
JP2023534808A5 JP2023503080A JP2023503080A JP2023534808A5 JP 2023534808 A5 JP2023534808 A5 JP 2023534808A5 JP 2023503080 A JP2023503080 A JP 2023503080A JP 2023503080 A JP2023503080 A JP 2023503080A JP 2023534808 A5 JP2023534808 A5 JP 2023534808A5
Authority
JP
Japan
Prior art keywords
costar
domain
signaling
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534808A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/042075 external-priority patent/WO2022016112A1/en
Publication of JP2023534808A publication Critical patent/JP2023534808A/ja
Publication of JP2023534808A5 publication Critical patent/JP2023534808A5/ja
Pending legal-status Critical Current

Links

JP2023503080A 2020-07-17 2021-07-16 養子細胞療法のための標的共刺激を提供する受容体 Pending JP2023534808A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053494P 2020-07-17 2020-07-17
US63/053,494 2020-07-17
PCT/US2021/042075 WO2022016112A1 (en) 2020-07-17 2021-07-16 Receptors providing targeted costimulation for adoptive cell therapy

Publications (2)

Publication Number Publication Date
JP2023534808A JP2023534808A (ja) 2023-08-14
JP2023534808A5 true JP2023534808A5 (enExample) 2024-07-17

Family

ID=77301001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503080A Pending JP2023534808A (ja) 2020-07-17 2021-07-16 養子細胞療法のための標的共刺激を提供する受容体

Country Status (10)

Country Link
US (2) US20220348631A1 (enExample)
EP (1) EP4182338A1 (enExample)
JP (1) JP2023534808A (enExample)
KR (1) KR20230088333A (enExample)
CN (1) CN116348485A (enExample)
AR (1) AR123004A1 (enExample)
AU (1) AU2021308702A1 (enExample)
CA (1) CA3189671A1 (enExample)
IL (1) IL299886A (enExample)
WO (1) WO2022016112A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ (ユーケイ) リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
CN116348485A (zh) 2020-07-17 2023-06-27 英研生物(英国)有限公司 提供用于过继性细胞疗法的靶向共刺激的受体
TW202306997A (zh) 2021-06-16 2023-02-16 英商英斯特生物科技有限公司 用於在過繼細胞療法中提供標靶共刺激之受體
WO2022271881A1 (en) * 2021-06-24 2022-12-29 Instil Bio, Inc. Methods of isolating of tumor infiltrating lymphocytes and use thereof
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
AU2023209445A1 (en) * 2022-01-20 2024-08-01 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy
US20240058447A1 (en) * 2022-05-25 2024-02-22 Instil Bio (Uk) Limited Use of fusion constructs for il-2 independent t cell therapy
EP4565683A1 (en) * 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024243429A2 (en) * 2023-05-24 2024-11-28 Instil Bio Inc. Use of fusion constructs for cd4+ t cell therapy
CN117947070A (zh) * 2024-02-01 2024-04-30 中山大学附属第三医院 一种嵌合抗原受体基因及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
WO2003008454A2 (en) * 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
SG11201507026WA (en) 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
EP3097117B1 (en) * 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
MX2018005618A (es) * 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
JP7012645B2 (ja) * 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
WO2017176525A1 (en) 2016-04-04 2017-10-12 Promab Biotechnologies, Inc. Car having replicated binding motifs in a co-stimulatory domain
US12083148B2 (en) * 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
KR102708285B1 (ko) 2017-03-13 2024-09-20 포세이다 테라퓨틱스, 인크. 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법
US11725210B2 (en) 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
EP3621988A1 (en) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
JP2020536531A (ja) * 2017-09-26 2020-12-17 ロングウッド ユニバーシティーLongwood University 免疫療法としてのpd1特異的キメラ抗原受容体
MA51428A (fr) * 2017-12-22 2020-11-04 Bluebird Bio Inc Récepteur d'antigène chimérique multivalent
JP7623939B2 (ja) 2018-07-09 2025-01-29 マルチチュード インコーポレーテッド 葉酸受容体アルファに特異的な抗体
GB201900858D0 (en) 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
WO2021048850A1 (en) 2019-09-11 2021-03-18 Migal Galilee Research Institute, Ltd. Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ (ユーケイ) リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
WO2022016114A1 (en) 2020-07-17 2022-01-20 Instill Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
CN116348485A (zh) 2020-07-17 2023-06-27 英研生物(英国)有限公司 提供用于过继性细胞疗法的靶向共刺激的受体
TW202306997A (zh) 2021-06-16 2023-02-16 英商英斯特生物科技有限公司 用於在過繼細胞療法中提供標靶共刺激之受體
WO2022271881A1 (en) 2021-06-24 2022-12-29 Instil Bio, Inc. Methods of isolating of tumor infiltrating lymphocytes and use thereof
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
US20230227576A1 (en) 2022-01-20 2023-07-20 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
US20240058447A1 (en) 2022-05-25 2024-02-22 Instil Bio (Uk) Limited Use of fusion constructs for il-2 independent t cell therapy

Similar Documents

Publication Publication Date Title
JP2021094037A5 (enExample)
JP2021087455A5 (enExample)
JP2025065142A5 (enExample)
KR102879284B1 (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
JP2019527557A5 (enExample)
JP2023123502A5 (enExample)
JP2018525033A5 (enExample)
JP2017524367A5 (enExample)
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール(miniGNC)抗体様タンパク質、その製造方法及び使用方法
JP2020513754A5 (enExample)
JP2025142045A5 (enExample)
JP2019525771A5 (enExample)
JP2022542543A5 (enExample)
JP2020533958A5 (enExample)
JP2021500881A5 (enExample)
JP2020512973A5 (enExample)
JP2020513829A5 (enExample)
JP2024502632A5 (enExample)
JP2024023228A5 (enExample)
JP2020525536A5 (enExample)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2022527144A5 (enExample)
JP2019524100A5 (enExample)
JP2021526844A5 (enExample)
JP2019521704A5 (enExample)